Exactly. The amounts are identical (6042 shares) and only option exercises, NOT open market purchases. Footnote is as you stated. Form 4's for Dec were nothing but option grants.
Subject to review of the Form 4s, those transactions may be part of the compensation for serving on the BOD. Check for a footnote on the 4s, when available, similar to this: 'The shares were issued to the Reporting Person under the Issuer's 2010 Stock Option and Incentive Plan and pursuant to the Issuer's compensation arrangements approved by the Board of Directors of the Issuer'.
"Save what you can and pick another biotech in this carnage of a market. Ampe is finished."
Almost finished, correct... They just have to sell Optina and provide another short squeeze, finish their current trial with very strong guidance given from the FDA on how to achieve success and than sell the company to a big pharma for $15/share... than it will be finished. But not until than. And it's coming.
Stevens David R, Giles Richard B, COELHO PHILIP H - Each bought shares of AMPE. That is the good sign. And expect a good news coming
Sentiment: Strong Buy
The problem is that many very promising DME treatments are already at Phase III and Fovista is very likely to be extended to DME after AMD Phase III. Iluvien was launched this year. It is extremely unlikely that Optina would ever be a preferred treatment for any significant fraction of patients. It might be a co-therapy as the PI noted, but the ROI is small IMO. They need to prove otherwise.
So, I just don't see high probability of a partner, especially one willing to pay upfront cash. If PIVOT fails like STEP and STRIDE there just isn't enough money left for another "final" Phase III trial.
BW, we know they dont have the money for phase 3 and they have to be aggressively seeking a partner. Probably not a bad idea for a early stage company that is out there that may want to add Optina to their portfolio and has the cash to do the phase 3. We could get some shares in that and for many early investors the spin offs alone will give you the returns based on cost average and the rest would be gravvy if you dumped the spin offs and hung on to ampe. I am still waiting for an end date on Ampion. They should be near completion.
What i find more interesting is that the price decline and volume correlation are not interrelated. Based on the 10 day MA and the 20 day moving average I am not seeing the volume associated with such declines. I think you touched on it when one looks at the broader market. It will be interesting to see if we get another repeat of the strut, stride and spring. All three times the pig moved above 8. I am still waiting for a shift in volume which I have not seen in a long time. Aytu actually has revenue producing products and with the history of Arbor this CEO could make good on a nice run up. Steve let us know when you see a reversal, I suspect it will be patterned with a nice volume day.
jd.fierre - - from a pragmatic perspective, I agree with the logic...and given the ratios you used, the AMPE pps share drop is not that unexpected (nor severe) because of the dilutionary effect caused by the spin out of AYTU...however, I recall a course on candlestick charting, i believe by steve nison, in which he mentioned that such events e.g. M&A, spin offs, partial sale of a public company, earnings, private capital injection, secondaries etc are "usually" well known by investors, traders and institutions and thus trades are made with that knowledge...and since charting is the study of what people are actually doing with their money and shares, all known information is built into price/volume action...it will be interesting to see how both entities trade...thanks for astute feedback
BTW, Dr. Michael Singer is a well respected expert in DME. That doesn't translate to pharmaceutical interest, but an estimate from him of the number of patients that could meaningfully benefit would be very valuable since he is fully independent of AMPE as far as I know. Potential conflicts of interest must be stated in conference proceedings.
Apparently most of the former promoters have left, otherwise the board would be filled with accolades for Optina based on today's announcement. Unfortunately, it's just an academic presentation, not a deal.
ANIK and FLXN ended the day essentially unscathed, but we continued to fall on heavier than avg vol.
Steve IMHO it may be difficult, for the next few weeks / months, to use historical price data (prior to Jan. 5) on AMPE, in order to analyze the stock on a technical basis. That's due to the spin-out of AYTU (1 share for every 5 of AMPE). AMPE closed at $3.31 on 1/4. So for every 1,000 shares, the valuation was $3,310. Following the distribution of AYTU, the dynamics have changed. At today's close, with AMPE at $2.38 and AYTU at $0.70, the combination is worth $2,520 ((1,000)(2.38)+(200)(0.70)).
moderate support here at 2.25 level...may be a double bottom support from July low...plus the 2.25 area is 100% fibonacci retracement from the July low to December recent high...a downside break here may slow once the May low close of 2.02 is kissed...volume, so far today is about 25% higher than the 20 day average - - - consistent with the sector's action...indicators, oscillators suggesting extreme oversold conditions in AMPE
but how is possible from 31 dec to today 3,50$ - 2,24$ without somthing......we are at the mimimum ...every day -11% who sell?